- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
Patent holdings for IPC class A61K 31/5365
Total number of patents in this class: 888
10-year publication summary
|
74
|
84
|
75
|
80
|
66
|
72
|
53
|
58
|
72
|
29
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| ImmunoGen, Inc. | 382 |
28 |
| Gilead Sciences, Inc. | 2207 |
27 |
| Shionogi & Co., Ltd. | 866 |
24 |
| Merck Sharp & Dohme LLC | 3737 |
23 |
| ViiV Healthcare Company | 165 |
21 |
| F. Hoffmann-La Roche AG | 7847 |
20 |
| Genentech, Inc. | 4090 |
19 |
| Merck Sharp & Dohme Corp. | 2183 |
16 |
| Eli Lilly and Company | 4050 |
15 |
| Novartis AG | 10338 |
12 |
| Janssen Pharmaceutica N.V. | 3213 |
12 |
| Hoffmann-La Roche Inc. | 3726 |
11 |
| Taisho Pharmaceutical Co., Ltd. | 855 |
11 |
| ViiV Healthcare UK (No. 5) Limited | 48 |
11 |
| Bristol-myers Squibb Company | 4789 |
10 |
| Boehringer Ingelheim International GmbH | 4494 |
10 |
| Board of Regents of the University of Nebraska | 793 |
9 |
| PRISM Pharma Co., Ltd. | 21 |
9 |
| The Global Alliance for TB Drug Development, Inc. | 41 |
8 |
| Glaxosmithkline Intellectual Property Development Limited | 774 |
6 |
| Other owners | 586 |